Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tuvalu Health Digest.
Press releases published on July 18, 2025
Le KFSHRC réalise la première implantation au monde d’un dispositif BiVAD assisté par robot
GlobeNewswire
·
July 18, 2025
RIYAD, Arabie saoudite, 18 juill. 2025 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital …
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
GlobeNewswire
·
July 18, 2025
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials Marseille, France, July 18, 2025, …
Press Release: Sanofi completes acquisition of Blueprint Medicines
GlobeNewswire
·
July 18, 2025
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and …
Communiqué de presse : Sanofi finalise l’acquisition de Blueprint Medicines
GlobeNewswire
·
July 18, 2025
Sanofi finalise l’acquisition de Blueprint Medicines Paris, le 18 juillet 2025. Sanofi annonce aujourd’hui la finalisation de l’acquisition de Blueprint Medicines Corporation (Blueprint). La nouvelle entreprise ajoute au portefeuille de Sanofi des …
SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
GlobeNewswire
·
July 18, 2025
Data supports further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma. SAN DIEGO, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Sapu Biosciences, LLC (Sapu), a wholly owned …
Successful Commercial Launch of Ryoncil®
GlobeNewswire
·
July 18, 2025
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil® (remestemcel-L-rknd) through the first …